Epigral credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
563563585963876
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
558558486956861
0.25×0.25×0.31×0.77×0.82×
0.25×0.25×0.26×0.76×0.81×
0.99×0.99×0.82×2.00×1.27×
0.96×0.98×0.68×1.99×1.25×
5.54×5.54×10.85×4.87×8.85×
20.2%20.2%23.5%43.4%45.0%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

EPIGRAL₹900.00

Epigral Limited

· Chemicals
₹ CrorePeersYASHOGUJALKALIFCLFOSECOINDVISHNUTATVAGALAXYSURFJUBLCPLMcap ₹3,883 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt876.1962.7584.6563.0563.0
Net Debt861.0955.9485.8557.5557.5
Total Debt/Equity0.820.770.310.250.25
Net Debt/Equity0.810.760.260.250.25
Total Debt/EBITDA1.272.000.820.990.99
Net Debt/EBITDA1.251.990.680.980.96
Interest Coverage (EBIT/Interest)8.854.8710.855.545.54
Total Debt/Total Capital %45.0443.4323.4920.2220.22
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.